Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Progress in ovarian cancer

L M Chen1, J S Berek

  • 1Department of Obstetrics & Gynecology, UCLA School of Medicine 90095-1740, USA.

Current Opinion in Obstetrics & Gynecology
|March 4, 1998
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Specific indicators of unsuitability for transarterial chemoembolisation in patients with intermediate-stage hepatocellular carcinoma according to thresholds of tumour burden and liver function as judged by survival benefit over sorafenib.

Hong Kong medical journal = Xianggang yi xue za zhi·2025
Same author

[Expert consensus on the clinical application of endometrial ablation].

Zhonghua fu chan ke za zhi·2025
Same author

Liver- and tumour-specific indicators predicting suboptimal survival following repeat transarterial chemoembolisation in patients with hepatocellular carcinoma.

Hong Kong medical journal = Xianggang yi xue za zhi·2025
Same author

[Analysis of clinical and imaging characteristics of neonatal arterial ischemic stroke with different long-term motor function prognoses].

Zhonghua er ke za zhi = Chinese journal of pediatrics·2025
Same author

[The 508th case: recurrent edema of bilateral lower extremities with proteinuria].

Zhonghua nei ke za zhi·2024
Same author

[A case of fibrillary glomerulonephritis with relatively slow progression].

Zhonghua nei ke za zhi·2024
Same journal

Management of hypertensive disorders in pregnancy.

Current opinion in obstetrics & gynecology·2026
Same journal

Updates in group prenatal care research.

Current opinion in obstetrics & gynecology·2026
Same journal

Complex benign gynecology in perimenopause: current evidence and future directions.

Current opinion in obstetrics & gynecology·2026
Same journal

Role of insulin in female reproduction.

Current opinion in obstetrics & gynecology·2026
Same journal

Urinary tract involvement in endometriosis: current evidence and clinical insights into navigating diagnosis and management.

Current opinion in obstetrics & gynecology·2026
Same journal

Updates in ultrasound imaging of adenomyosis and clinical impacts.

Current opinion in obstetrics & gynecology·2026
See all related articles

Aggressive surgical cytoreduction is crucial for advanced ovarian cancer management. While new chemotherapy agents show promise, the best initial treatment regimen remains under investigation.

Area of Science:

  • Gynecologic Oncology
  • Surgical Oncology
  • Medical Oncology

Background:

  • Advanced ovarian cancer management necessitates optimal surgical debulking and chemotherapy.
  • Recent studies reinforce the benefits of aggressive cytoreduction, even in advanced stages (Stage IV) and second-look surgeries.

Purpose of the Study:

  • To review the current evidence supporting aggressive surgical cytoreduction in advanced ovarian cancer.
  • To discuss the evolving landscape of adjuvant chemotherapy for ovarian cancer.

Main Methods:

  • Review of recent clinical studies and surgical outcome data.
  • Analysis of ongoing research into novel chemotherapeutic agents for ovarian cancer.

Main Results:

  • Continued evidence supports maximal surgical cytoreduction as a key component of treatment for advanced ovarian cancer.

Related Experiment Videos

  • Several active chemotherapeutic agents have been identified, but a definitive optimal first-line regimen is still lacking.

    • Conclusions:

    • Aggressive surgical cytoreduction remains a cornerstone in the management of advanced ovarian cancer.
    • Further research is required to establish the optimal first-line chemotherapy regimen for ovarian cancer patients.